Literature DB >> 12556669

Optimal treatment of hypertension and cardiovascular risk reduction in African Americans: treatment approaches for outpatients.

Jackson T Wright1, Janice Douglas.   

Abstract

African Americans have a higher prevalence and greater severity of hypertension compared with whites and therefore have a higher prevalence of many disease-related complications, such as coronary heart disease, stroke, and end-stage renal disease. Minorities have been, until recently, underrepresented in large clinical trials, leading to a lack of outcome data for these patient groups. However, accumulating data confirm the benefit of aggressive blood pressure-lowering therapy in this population. These studies also show that most patients require combination therapy to achieve adequate blood pressure reduction, particularly high-risk patient groups that have lower target blood pressure goals. All of the available antihypertensive agents are effective in African Americans. Recent studies suggest that regimens containing a thiazide-type diuretic are unsurpassed in blood pressure lowering and prevention of major clinical complications, and they cost less. Thus, while other agents may be required for selected clinical indications or for blood pressure control, diuretics should be drugs of first choice or included in most antihypertensive regimens especially in African American hypertensives. Copyright 2003 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556669      PMCID: PMC8101892          DOI: 10.1111/j.1524-6175.2003.02180.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  25 in total

1.  Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group.

Authors:  J D Neaton; D Wentworth
Journal:  Arch Intern Med       Date:  1992-01

Review 2.  Coronary heart disease in African Americans: primary and secondary prevention.

Authors:  L T Clark; O Emerole
Journal:  Cleve Clin J Med       Date:  1995 Sep-Oct       Impact factor: 2.321

3.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.

Authors:  J T Wright; W C Cushman; B R Davis; J Barzilay; P Colon; D Egan; T Lucente; C Nwachuku; S Pressel; F H Leenen; J Frolkis; R Letterer; S Walsh; J N Tobin; G E Deger
Journal:  Control Clin Trials       Date:  2001-12

4.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Authors:  C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

Authors:  V L Burt; P Whelton; E J Roccella; C Brown; J A Cutler; M Higgins; M J Horan; D Labarthe
Journal:  Hypertension       Date:  1995-03       Impact factor: 10.190

10.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

View more
  1 in total

Review 1.  Ethnicity and blood pressure.

Authors:  Suzanne Oparil; Jackson T Wright
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-06       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.